Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records β€” linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review claims


     Quick Explanation



    Nicolas Rohner (ORCID 0000-0003-3248-2772) is a highly productive evolutionary geneticist (h-index 34; ~5,600 citations; 153 works) whose cavefish work on HSP90 buffering, insulin resistance, and single-cell brain atlases shows strong rigor and high novelty; however, the supplied citation-metrics list (h-index 2; 10 unrelated papers on LSD perception and space education) appears to be a name-homonym mismatch and was not used to judge him.


     Long Explanation



    Identity and citation-metrics: a critical data conflict

    The supplied author-citation record (h-index 2, 20 citations, papers on LSD perception, planetary defence, and DLR solar-furnace thermometry) is almost certainly a different person sharing the name: the OpenAlex profile matched to ORCID 0000-0003-3248-2772 shows 153 works, ~5,612 citations, h-index 34, and topics dominated by genetics and evolutionary biology β€” fully consistent with the HSP90 cavefish and single-cell atlas papers supplied. Per OpenAlex, this Rohner's citations peaked around 2013–2018, driven by the African coelacanth genome (~701 citations), the cavefish genome paper (~322), and the insulin-resistance cavefish Nature paper (~276). This review evaluates the evolutionary-genomics profile and flags the homonym risk explicitly rather than averaging two incompatible records.

    Synthetic strengths: mechanism, environment, and genomic scale

    The HSP90 capacitor study (Science, 2013) is the flagship: HSP90 inhibition (500 nM radicicol) increased eye-size SD by +58–83% and orbit-size SD by +108% in surface Astyanax mexicanus (Bartlett/Levene P < 0.001), while cave-like low conductivity mimicked the effect (+50–58% variation), and selection on treated lines produced heritable eye reduction without drug (P = 7.2e-16) β€” an unusually complete demonstration of buffering, release, and genetic assimilation in a natural population . His group then translated metabolic cave adaptations (MC4R mutations; insulin resistance) into clinically relevant diabetes biology . Most recently, a snRNA-seq/spatial atlas (117,000 nuclei, 35 clusters) maps cave-adaptation to coordinated circadian, HIF1A, immune, and glia-to-neuron signaling remodeling β€” observational but with a falsifiable pathway-level design and full data release (GEO GSE335564) .

    Rigor, limitations, and epistemic honesty

    Weaknesses are visible in the records: small samples in some assays (e.g., n=1 per group for hematopoietic flow cytometry in the Tol2 transgenesis paper) ; radicicol off-target effects; cross-species orthology projection in pathway interpretation; and inferred (not exhaustively demonstrated) causality between HSP90 buffering and natural eye loss. Funding is conventional NIH/NSF/institute support; one co-author on the HSP90 paper disclosed a consultant conflict, unrelated to the biology. Strengths: trait-level negative controls (dark rearing alone had no effect; body size and neuromasts showed no cryptic variation), appropriate variance tests, and a null-grouping control in the atlas (random grouping yielded only 3 DEGs). What would change the assessment: failure of independent labs to replicate the assimilation phenotype, or cell-number-driven artifacts in the immune atlas analyses.

    Confidence: high on the evolutionary-genomics profile (multiple independent high-impact papers); low on the homonym-corrected metrics because the two supplied profiles conflict.



    Feedback:    

    Updated: September 08, 2026

     BGPT Author Review



    Scientific Quality

    90%

    High-impact, mechanism-to-genome evolutionary biology: senior/co-author roles on Nature/Nature Genetics genomes (coelacanth, cavefish), a first-tier Science paper demonstrating HSP90 capacitation with genetic assimilation, and translational metabolic findings (insulin resistance). Metrics (h-index 34, ~5.6k citations) match a mid-career leader. Weaknesses: some resource papers have small validation samples, and causality in field contexts remains partly inferential. The supplied low-citation profile is a homonym and excluded.



    Communication Quality

    80%

    Papers report precise statistics, clear organism/treatment framing, and release data (GEO, UCSC Cell Browser, Stowers repositories), aiding reproducibility and accessibility. Some translational claims (e.g., diabetes relevance) are interpretive and could be more explicitly hedged for broader audiences; some methods details (sample sizes) are thin in places.



    Author Novelty

    90%

    First demonstration of HSP90 as a capacitor for morphological evolution in a natural vertebrate population, plus novel single-cell brain atlas of cave adaptation β€” both opened new subfields. Tol2 transgenesis is methodological rather than conceptual novelty.



    Scientific Rigor

    80%

    Multiple variance tests (F, Bartlett, Levene), null-grouping controls, negative controls (dark rearing), orthogonal stress mimicry, and heritability assays strengthen causal chains. Deductions: no blinding reported, n=1 hematopoietic assay, off-target pharmacology unaddressed, orthology-based pathway inference, and assimilation causality inferred not proven.

     Top Data Sources ExportMCP



     Hypothesis Graveyard



    Cave eye loss is caused by darkness-induced developmental plasticity β€” falsified here: dark rearing alone had no effect on eye size; heritable genetic assimilation was demonstrated in the absence of drug.


    Cavefish metabolic syndrome is simply maladaptive diabetes-like pathology β€” superseded: insulin resistance and MC4R loss are adaptive to nutrient-poor caves, showing glucose sparing rather than pathology.

     Science Art


    Author Review: Nicolas Rohner Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT